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The putative role of TP53 and p16INK4A tumor suppressor genes and Ras oncogenes in the development and progression of salivary
gland neoplasias was studied in 28 cases of pleomorphic adenomas (PA), 4 cases of cystic adenocarcinomas, and 1 case of
carcinoma ex-PA. Genetic and epigenetic alterations in the above genes were analyzed by Polymerase Chain Reaction/Single
Strand Conformational Polymorphism (PCR/SSCP) and sequencing and byMethylation Specific-PCR (MS-PCR). Mutations in TP53
were found in 14% (4/28) of PAs and in 60% (3/5) of carcinomas.Mutations inH-Ras and K-Raswere identified in 4% (1/28) and 7%
(2/28) of PAs, respectively. Only 20% (1/5) of carcinomas screened displayed mutations in K-Ras. p16INK4A promoter
hypermethylationwas found in 14% (4/28) of PAs and 100% (5/5) carcinomas. All genetic and epigenetic alterationswere detected
exclusively in the epithelial and transitional tumor components, and were absent in the mesenchymal parts. Our analysis suggests
that TP53mutations and p16INK4A promoter methylation, but not alterations in theH-Ras and K-Ras genes, might be involved in the
malignant progression of PA into carcinoma. J. Cell. Physiol. 207: 654–659, 2006.  2006 Wiley-Liss, Inc.
Salivary gland (SG) neoplasias are quite rare,
accounting for approximately 2–3% of head and neck
tumors (De Vita et al., 2001). Most SG tumors are benign
and are generally pleomorphic adenomas (PAs). SG
tumors are characterized by an extremely varied
histomorphological phenotype due to combinations of
different epitheliomorphic and mesenchymomorphic
features. The molecular mechanisms determining these
two histomorphological types and their coexistence in
SG tumors are not fully understood, with many aspects
of their histogenesis still under discussion. Two relevant
theories have been proposed: the ‘‘different cell’’ theory
suggests that SG neoplasias originate from two distinct
cell populations, that is, mesenchymal and (myo-)
epithelial (Soini and Autio-Harmainen, 1993; Su et al.,
1993). The ‘‘single-cell’’ theory suggests that SG tumors
develop in the process of epithelial–mesenchymal
transition (Welsh and Meyer, 1968; Dardick et al., 1983).
Approximately 2–9% of PAs become malignant,
evolving into carcinoma ex-pleomorphic adenoma that
is characterized by frequent infiltrations of the sur-
rounding, parenchyma and metastatic spreading (Chen,
1978; Gnepp, 1993; Ellis and Auclair, 1995). The most
common form of SG malignancy is the cystic adenoid
carcinoma, a fairly slow-growing tumor with a tendency
for perineural invasion and hematogenous metastasis to
the lungs and bones (Bell et al., 2005).
The critical role of different genetic and epigenetic
alterations in carcinogenesis has been recognized for
some time; some of the most important events in the
transformation of normal cells into malignant cells
involve mutations in genes encoding the Ras family
proteins (Giehl, 2005) and the oncosuppressor TP53
(Papadaki et al., 1996; Steele et al., 1998) as well as the
methylation of the p16INK4A gene promoter (Das and
Singal, 2004). Little is known about their role in the
development of SG tumors (Kishi et al., 2005).
Consequently, the aim of our study was to analyze the
frequency of TP53, H-Ras, and Ki-Ras gene alterations
and to assess the methylation status of the p16INK4A
gene promoter in SG tumors. Furthermore, we exam-
ined whether these genetic and epigenetic alterations




A prospective study was performed on tumor samples from a
consecutive series of 33 patients who underwent resective
surgery for primary operable SG at the Department of
Oncology, University of Palermo, Italy. All resection specimens
and microscopic slides were examined by two independent
pathologists (R.M.T. and V.M.) who were blinded to the
original diagnosis and the results of molecular analyses. The
complete excision of the primary tumor was histologically
proven by examination of the resected margins. The study
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material included 28 PAs, 4 cystic adenocarcinomas, and 1
carcinoma ex-pleomorphic adenoma. Tissues were fixed in 70%
ethyl alcohol and paraffin-embedded. At least three single
sections were analyzed from each paraffin-embedded tissue.
One of the sections was used for microdissection followed by
mutational analysis, while the others were used for immuno-
histochemistry experiments.
Laser-pressure catapulting (LPC) and DNA extraction
Five-micrometer sections of paraffin-embedded tissue speci-
mens, prepared using a microtome, were mounted on the
supporting LPC membrane placed on the slide. The samples
were pretreated with xylene for 10 min and rehydrated using
decreasing grade alcohols (100%, 95% 50% ethanol) and H2O.
Then the slides were stained with hematoxylin and eosin and
dehydrated using increasing graded alcohol. LPC was per-
formed using a Zeiss inverted microscope PALM Laser Micro-
Beam System UV laser at 337 nm. Before performing
microdissection, 1 ml of mineral oil was placed on the samples
(Bazan et al., 2005b). The areas to be dissected were selected by
means of extremely high-precision microcuts (the specimens
ranged from as little as 1 mm to 1,000 mm in diameter). LPC
dissection was performed using a few shots each of 100 mm in
diameter. After catapulting, the material was removed from
the cap for genetic analysis. Genomic DNA from tumor and
normal specimens was extracted using the QIAamp Tissue Kit
(Qiagen, Hilden, Germany) following standard protocol.
Detection of TP53, H-Ras and Ki-Ras gene mutations
Normal and tumor samples were used to screen for
mutations within the TP53, Ki-Ras, and H-Ras genes using
Single Strand Conformational Polymorphism (SSCP) analysis.
PCR amplification of the exons 5–8 for TP53 and exon 1 for H-
Ras and K-Ras (Table 1) was performed as previously described
(La Farina et al., 1998). The abundance and integrity of the
amplification products were verified by 1.5% agarose gel
electrophoresis and ethidium bromide staining. One hundred
nanogram aliquots of the PCR products, purified and concen-
trated by filtration through Microcon 50 columns (Amicon,
Beverly, MA), were denatured and used for SSCP analysis.
Individual ssDNA fragments exhibiting shifted mobilities
relative to normal controls, were electroeluted from polyacry-
lamide gel, as described previously (Russo et al., 2002),
reamplified, and sequenced. The characterization of single
mutations was performed by automated sequencing using the
Big Dye Terminator Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA) and the model 3100 DNA sequencer
(Perkin-Elmer, Foster City, CA).
Cytokeratin and vimentin immunohistochemistry
Paraffin-embedded sections from alcohol-fixed tissues of all
PA cases were immunostained with monoclonal antibodies
(Abs) against cytokeratin and vimentin in order to identify the
epithelial and mesenchymal components, respectively. Two
micrometer sections were pretreated with xylene for 10 min
and rehydrated using decreasing graded alcohols (100%, 95%,
50%, ethanol) and H2O. Endogenous peroxidase activity was
blocked by incubating the samples in 3% hydrogen peroxide for
10 min followed by a phosphate-buffered saline (PBS) wash.
The sections were then simultaneously immunostained with a
mixture of monoclonal Abs against cytokeratin (clone MNF116,
dilution 1:50, Dako, Denmark) and vimentin (clone V9,
dilution 1:100, BioGenex, Netherlands) for 30 min at room
temperature. Applying the indirect peroxidase-antiperoxidase
(PAP) method by a standard peroxidase-labeled streptavidin-
biotin procedure (LSABþSystem-HRP, Dako), the sections
were incubated with the biotinylated secondary Ab and then
with a mix of streptavidin-horseradish peroxidase-labeled.
Detection of the antigens was performed with the use of AEC
Substrate-Chromogen kit (Dako-AEC); the slides were then
counterstained with Meyer’s hematoxylin.
Methylation status of p16INK4A locus
Normal and tumor samples were analyzed using the
CpGenome DNA Modification kit (Intergene Company) follow-
ing manufacturer’s instructions. Peripheral blood leukocytes
(PBL) were used as negative controls and universal methy-
lated DNA (ONCOR, Geithersburg, MD) was used as a positive
control. DNA was modified with bisulfite treatment. Specifi-
cally, 2mg of DNA were denatured using 0.2 M NaOH for 10 min
at 378C. Then, DNA Modification Reagent I was added and the
mixture was incubated for 18 h at 508C, and subsequently
treated with DNA Modification Reagents II and III in 50 ml of
water. The modification of DNA was completed with 0.3 M
NaOH treatment for 5 min, followed by ethanol precipitation.
The modified DNA was amplified by PCR using specific
primers (Table 1) to distinguish methylated and unmethylated
regions. The size and integrity of the amplification products
were verified by 2% agarose gel electrophoresis and ethidium
bromide staining.
RESULTS
Analysis of genetic and epigenetic alterations
in SG tumors
TP53 mutations. The mutational analyses of exons
5 to 8 of the TP53 gene identified 8 TP53 alterations
in 28 (28%) PAs screened. The particular features of
these alterations are shown in Table 2. Twenty-five
percent (2/8) of the mutations were found in exon 5, 50%
(4/8) in exon 6 and 25% (2/8) in exon 7; no mutations were
identified in exon 8. All mutations were single-nucleo-
tide substitutions. 50% percent of TP53 mutations were
missense (4/8), and 50% (4/8) were silent mutations.
Among these alterations, transversions (7/8, 87%) were
far more frequent than transitions (1/8, 13%) (Fig. 1)
(Table 2). One mutation occurred in highly conserved
domains (areas II–V). Considering the specific func-
tionalandstructuraldomainsofTP53protein (Choetal.,
1994), one mutation occurred in the L2 loop.
In the cases of carcinoma ex-pleomorphic adenoma
and cystic adenoid carcinomas, 4 TP53 mutations were
found; 50% (2/4) of those occurred in exon 5, 25% (1/4) in
exon 6, and 25% (1/4) in exon 7. All mutations proved to
be single-nucleotide substitutions, of which 75% (3/4)
were missense mutations, and 25% (1/4) encoded silent
mutations (Table 2). All (4/4) mutations were transver-
sions. Twenty-five percent of the mutations (1/4)
occurred in highly conserved TP53 domains. Function-
ally, 25% of mutations (1/4 cases) were in the L2 loop and
25% in the L3 loop.
H-Ras and Ki-Ras mutations. In the analyzed PA
cases, 4% (1/28) and 7% (2/28) of the missense mutations
were found in codon 13 of H-Ras and Ki-Ras, respec-
tively. A high number of cases 8/28 (28%) displayed
a silent mutation in exon 1 (codon 27 His27His
CAT>CAC) of H-Ras. In the SG carcinomas analyzed,
we identified a missense mutation in codon 13 in one
TABLE 1. Oligonucleotide primers for p53, H-ras, K-ras, and
p16 genotyping
Exon Primer sequences Anneal, 8C
ex5 p53 50-caa cca gcc ctg tcg tct ctc-30 58
50-ctg ttc act tgt gcc ctg ac-30
ex6 p53 50-cct cac tga ttg ctc tta gg-30 50
50-agt tgc aaa cca gac ctc a-30
ex7 p53 50-caa gtg gct cct gac ctg ga-30 58
50-tcc tag gtt ggc tct gac-30
ex8 p53 50-tcc tgc ttg ctt acc tcg-30 54
50-tcc tat cct gag tag tgg t-30
h-ras 50-ctg agg agc gat gac gga ata taa gc-30 68
50-ctc tat agt ggg gtc gta ttc gtc ca-30
k-ras 50-gtg tga cat gtt cta ata tag tca ca-30 58
50-gaa tgg tcc tgc acc agt aa-30
p16M 50-tta tta gag ggt ggg gcg gat cgc-30 61
50-gac ccc gaa ccg cga ccg taa-30
p16U 50-tta tta gag ggt ggg gtg gat tgt-30 66
50-cca ccc caa acc aca acc ata a-30
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case (25%), and silent mutations in codon 27 of H-Ras in
two cases (50%). No mutations in Ki-Ras were observed
(Table 2).
Methylation status of the p16INK4a gene. The
analysis of the methylation status of the p16INK4a gene
promoter revealed that 14% (4/28) of the PAs examined
showed aberrant methylation within the CpG island.
Furthermore, in all the cases (5/5) of carcinoma ex-
amined, we found hypermethylation of the p16INK4a
promoter (Fig. 2) (Table 2).
Multiple genetic and epigenetic alterations. Mul-
tiple alterations were found in 10% (3/28) of the analyzed
PA cases; one case presented a double mutation in exons
5 and 7 of TP53 (codon 143 Val-Met, GTG>ATG and
codon 233 Ist-Pro CAC>CCC), while the remaining
cases showed methylation of the p16INK4a promoter as
well as alterations in exon 1 of both H-Ras (codon 13 Gly-
Ala GGT>CGT) and Ki-Ras (codon 13 Gly-Ala GGC>
GCC).
It is interesting to note that two triple alterations were
observed in the five cases of carcinoma examined.
Specifically, in addition to the methylation of p16INK4a,
our study showed either a double mutation ofTP53 gene
(codon 166 Ser-Pro TCA>CCA and codon 249 Arg-Ser
AGG>AGT) or single mutation of TP53 gene (codon 143
Val-Met GTG>ATG) and H-Ras (codon 13 Gly-Ala
GGT>CGT) (Table 2).
Analysis of genetic and epigenetic alterations in
the epithelial and mesenchimal components
In the examined PA cases, only the epithelial com-
ponent exhibited H-Ki-Ras missense mutations, TP53
mutation, and methylation of the p16INK4a promoter,
whereas the mesenchymal and transitional cells were
not mutated. All H-Ki Ras and TP53 mutations, and
p16INK4a methylations detected occurred in the epi-
thelial component of the tumor, as defined by immuno-
histochemistry prior to microdissection. In the
mesenchymal areas, which were negative for cytoker-
atin, and positive for mesenchymal markers, no genetic
alterations in H-Ki-Ras, TP53, and p16INK4a were
detected (Figs. 2 and 3).
DISCUSSION
Substantial clinical and experimental evidence sup-
ports the claim that alterations in the TP53 and
p16INK4A tumor suppressor genes and in Ras oncogenes
play a critical role in tumorigenesis (Serrano et al., 1996;
Bazan et al., 2002; Iacopetta, 2003). The importance of
TP53andRasgene mutations has been particularly well
defined in the model of colorectal cancer (CRC) (Fearon
and Vogelstein, 1990; Hsieh et al., 2005) where both of
these alterations are now accepted prognostic markers
(Russo et al., 2005). Furthermore, specific TP53 muta-
tions, more than any mutations, are biological indicators
of CRC progression and outcome (Bazan et al., 2005a).
The alteration in the gene encoding p16INK4A has been
well studied in different types of tumors, especially in
melanoma and pancreatic cancer where it plays an
important role during tumorigenesis or tumor progres-
sion (Bartsch et al., 1995; Bahuau et al., 1998).
Until now, only few studies examined the above
genetic alterations in SG tumors. These limited data
have not explained the role that TP53, Ras and p16INK4A
TABLE 2. TP53, K-H ras, p16INK4 genotyping dataa
Case Diagnosis TP53 mutation Kras mutation Hras mutation
p16INK4
alteration
1 Pleomorphic adenoma WT WT Mut Gly13Ala GGT-CGT M
2 Pleomorphic adenoma WT WT WT U
3 Pleomorphic adenoma WT WT WT U
4 Pleomorphic adenoma WT Mut Gly13Ala GGC>GCC WT M
5 Pleomorphic adenoma WT WT WT U
6 Pleomorphic adenoma WT WT WT U
7 Pleomorphic adenoma WT WT WT U
8 Pleomorphic adenoma WT WT Pol His27His CAT>CAC U
9 Pleomorphic adenoma WT WT WT U
10 Pleomorphic adenoma WT WT WT U
11 Pleomorphic adenoma Pol ex6 Arg213Arg CGA>CGG WT Pol His27His CAT>CAC U
12 Pleomorphic adenoma WT WT WT U
13 Pleomorphic adenoma WT WT WT U
14 Pleomorphic adenoma WT WT WT U
15 Pleomorphic adenoma Mut ex5 Val143Met GTG>ATG WT WT U
Mut ex7 His233Pro CAC>CCC
16 Pleomorphic adenoma Mut ex5 Pro128Ala CCT>GCT WT WT U
Pol ex6 Arg213Arg CGA>CGG
17 Pleomorphic adenoma WT WT WT M
18 Pleomorphic adenoma WT WT Pol His27His CAT>CAC U
19 Pleomorphic adenoma WT WT WT M
20 Pleomorphic adenoma Mut ex5 Ser166Pro TCA>CCA WT WT U
21 Pleomorphic adenoma WT WT WT U
22 Pleomorphic adenoma WT WT Pol His27His CAT>CAC U
23 Pleomorphic adenoma WT WT WT U
24 Pleomorphic adenoma WT WT WT U
25 Pleomorphic adenoma Pol ex6 Arg213Arg CGA>CGG WT WT U
26 Pleomorphic adenoma WT WT Pol His27His CAT>CAC U
27 Pleomorphic adenoma WT WT Pol His27His CAT>CAC U
28 Pleomorphic adenoma Pol ex6 Ser211Ser CGA>CGG Mut Gly13Ala GGC>GCC Pol His27His CAT>CAC U
29 Adenoid cystic carcinoma WT WT WT M
30 Adenoid cystic carcinoma Pol ex6 Ser211Ser CGA>CGG WT WT M
31 Adenoid cystic carcinoma Mut ex5 Ser166Pro TCA>CCA WT Pol His27His CAT>CAC M
Mut ex7 Arg249Ser AGG>AGT
32 Adenoid cystic carcinoma Mut ex5 Val143Met GTG>ATG WT Mut Gly13Ala
GGT>CGT
M
33 Adenoid pleomorphic carcinoma WT WT Pol His27His CAT>CAC M
aWT, wild-type; Mut, mutation; Pol, polymorhism; ex, exon; M, methylated; U, unmethylated.
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might play in the etiology and progression of SG tumors.
In addition, our study is the first one addressing the
possible cooperation of the studied genetic and epige-
netic alterations in SG cancer progression.
Point mutations in the TP53 tumor suppressor gene
are the most common cancer-related genetic abnorm-
ality in human malignancy. Previous analyses of dif-
ferent types of tumors have shown that most of TP53
mutations affect exons 5–8, especially residues 130–
286 encoding TP53 DNA-binding domain and the region
controlling folding and stabilization of tertiary struc-
ture. Only rarely have mutations outside exons 5–8
been identified, including those in the introns of the
splicing sites, which probably give rise to an aberrant
RNA splicing (18). We found a fairly high rate (14%) of
mutations in TP53 DNA, which is higher than the rate of
mutations (10%) reported in the single published
study on the subject (Weber et al., 2002a). The higher
incidence of TP53 mutations observed by us could be
related to a more sensitive and accurate methodology
(SSCP and then sequencing) (15), when compared with
methodology (direct sequencing) used by other authors.
Also, the phenotype of SG tumors examined could reflect
different environmental and dietary factors, which
might contribute to the cancerogenesis (Zheng et al.,
1996).
Normal growth factor-dependent Ras signaling can be
bypassed by mutations in codons 12, 13, and 61, leading
to functional redundancy of the intrinsic activity of
GTPase and constitutive activation of downstream
pathways and, in consequence, increased mitogenesis
(Milasin et al., 1993; Okutsu et al., 1993). The role of Ras
oncogenes in SG tumors, and particularly in PAs, is still
not fully understood. In fact, no published reports
addressed the frequency of mutations in exon 1–2 in
theK-Ras gene in such tissue. Our present study, which
shows a mutation rate of 7%, is therefore the first
relevant work. By analyzing exon 1 of H-Ras, we
identified a missense mutation rate of 4% and a silent
mutation rate of 28%; the latter type of alteration is often
found in the healthy population (Perrone et al., 2003).
Notably, the H-Ras alterations in PA were reported in
only one previous study that employed hybridization
with synthetic oligonucleotide probes (Milasin et al.,
1993).
The p16INK4a tumor suppressor gene is inactivated by
mutation, homozygous deletion, or gene methylation. It
has been shown that hypermethylation of the p16INK4a
promoter is frequent in some primary tumors such as
lung, pancreatic cancer (Sherr and McCormick, 2002).
A recent study of 42 cases of PA of SG has shown that
p16INK4a does not present microdeletions or specific
mutations in any exon, but in 28% of cases there was
Fig. 1. SSCP analysis of exons 5 and 7 (A and B) of TP53 gene
amplified from adenoid cystic carcinoma (Case 31) and genomic DNA
from normal tissue from one patient (Case 29). In A and B, tumor DNA
is on the right (WT) and normal tissue DNA is on the left (N). The
extra bands visualized by SSCP correspond to ssDNA molecules
haboring mutations in exon5 Ser166Pro TCA>CCA and in exon7
Arg249Ser AGG>AGT, as confirmed by sequencing (C and D).
Fig. 2. p16INK4a analysis using MSP in one pleomorphic adenoma
(Case 4). Bisulfite-treated DNA (which changes the unmethylated but
not the methylated cytosines into uracil) is subjected to PCR
amplification using primers designed to anneal specifically to the
methylated bisulfite-modified DNA. MSP results are expressed as
unmethylated p16INK4a-specific bands (U) or methylated p16INK4a-
specific bands (M). Normal lymphocytes (NL) and in vitro methylated
DNA (IVD) are used as negative and positive controls, respectively.
Case 4 with methylated p16INK4a within the epithelial tumor (Cyt,
cytokeratin), but not in the mesenchymal component (Vim, vimentin).
The last lane contains 100 bp DNA ladder.
Fig. 3. Typical image of the LPC process involving epithelial tissue
immunostained with mAbs against cytokeratin placed on a slide after
the addition of a 1 ml of mineral oil. A and B: Cutting and catapulting
of the gland. The images are at 40 magnification; (C) catapulted
gland on the eppendorf cap; 5 magnification. [Color figure can be
viewed in the online issue, which is available at www.interscience.
wiley.com.]
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methylation of the p16INK4a promoter, which correlated
with loss of mRNA transcription (Weber et al., 2002b).
Our present analyses showed a hypermethylation rate
of 14% of the promoter of the tumor oncosuppressor gene
p16INK4a. This difference between our study and the
other report is probably due to dietary habits (Davis and
Uthus, 2004).
The population of adenoid cystic carcinomas and
carcinoma ex-pleomorphic adenoma analyzed by us
included several tumors that probably originated from
preceding pleomorphic adenomas. In accordance with
previously published reports, these tumors were char-
acterized by a high rate of TP53 missense mutations
(three of five cases) a fairly high rate of H-Ras missense
mutations (one of five cases), and a low rate of K-Ras
mutations (one of five cases). In fact, some authors
described a fairly high percentage of TP53 gene muta-
tions in salivary gland carcinomas, (66–22%) (Papadaki
et al., 1996; Zhang et al., 2004), while K-Ras and H-Ras
mutations were found in 5–35% and 0–8% of salivary
gland carcinoma cases (Yamamoto et al., 1996; Yoo and
Robinson, 2000).
In our study, we described methylation of the p16INK4a
promoter in five out of five cases. Other reports described
the different rates of p16INK4a promoter methylation in
SG tumors, from 11% to 47% (Nishimine et al., 2003; Li
et al., 2005). It is possible that these data differ from our
own because their studies were performed without the
use of microdissection techniques and also because they
refer to analyses regarding Oriental populations.
Very little is known about the molecular mechanisms
of carcinogenesis in SG tumors developing from PAs. We
carried out separate analysis of mesenchymal and
epithelial components obtained by immunohistochem-
istry followed by microdissection, not only in order to
distinguish the epithelial, mesenchymal, and transi-
tional areas, but also to avoid false-positive or false-
negative results, which may often be brought about by
contamination with inflammatory cells or fibrotic areas.
As Weber et al. (2002b) have already reported, in PAs,
methylation of p16INK4A and TP53 mutations occur only
in the epithelial component, which suggests that it is
these areas of the adenoma which potentially evolve into
a carcinoma.
In conclusion, our analysis found a low rate of H-Ras
and Ki-Ras missense mutations in all types of SG tumors
studied, suggesting that the Ras oncogens might be not
involved in the malignant evolution of SG PA into SG
carcinoma. On the other hand, the frequency of TP53
mutations and methylation of the p16INK4A was sig-
nificantly greater compared to that of Ras mutations.
Moreover, we observed the accumulation of alterations
in these genes in SG carcinomas. Thus, future analyses
of TP53 mutations and p16INK4A methylation might be
useful for discriminating between benign and malignant
SG tumors and to evaluate the prognostic value of these
mutations.
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